We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Very-Low-Density-Lipoprotein-Triglyceride(VLDL-TG) Metabolism During Acute Hyperglycemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01178957
Recruitment Status : Completed
First Posted : August 10, 2010
Last Update Posted : August 7, 2013
Information provided by (Responsible Party):
University of Aarhus

Brief Summary:
The purpose of this study is to estimate the acute effect of hyperglycemia on Very-Low-Density-Lipoprotein-triglyceride(VLDL-TG) secretion.

Condition or disease Intervention/treatment
Type 1 Diabetes Other: Hyperglycemia

Study Type : Observational
Actual Enrollment : 8 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Very-Low-Density-Lipoprotein-Triglyceride(VLDL-TG) Metabolism During Acute Hyperglycemia
Study Start Date : April 2012
Primary Completion Date : April 2013
Study Completion Date : April 2013

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Group/Cohort Intervention/treatment
Type 1 diabetes Other: Hyperglycemia
Hyperglycemia with a blood glucose of 15 mmol/L

Primary Outcome Measures :
  1. Very-Low-Density-Lipoprotein-Triglyceride(VLDL-TG) secretion [ Time Frame: 8 hours ]
    Very-Low-Density-Lipoprotein-Triglyceride(VLDL-TG) kinetics over a single study day

Biospecimen Retention:   Samples With DNA
Blood Samples

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Type 1 diabetics

Inclusion Criteria:

  1. Type 1 diabetes
  2. Age 18-50 years

Exclusion Criteria:

  1. Smoking
  2. Alcohol abuse
  3. Use of medications (except insulin in diabetics)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01178957

Department of Endocrinology MEA, Aarhus Hospital
Aarhus C, Denmark, 8000
Sponsors and Collaborators
University of Aarhus

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: University of Aarhus
ClinicalTrials.gov Identifier: NCT01178957     History of Changes
Other Study ID Numbers: ES-0004
First Posted: August 10, 2010    Key Record Dates
Last Update Posted: August 7, 2013
Last Verified: August 2013

Keywords provided by University of Aarhus:
Type 1 diabetes

Additional relevant MeSH terms:
Diabetes Mellitus, Type 1
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases